Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed at $2.66 in the last session, up 5.56% from day before closing price of $2.52. In other words, the price has increased by $5.56 from its previous closing price. On the day, 1.64 million shares were traded. AMLX stock price reached its highest trading level at $2.7 during the session, while it also had its lowest trading level at $2.535.
Ratios:
We take a closer look at AMLX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.66 and its Current Ratio is at 4.66. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on March 18, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $32 previously.
On March 11, 2024, Robert W. Baird Downgraded its rating to Neutral which previously was Outperform and also lowered its target price recommendation from $37 to $4.
Leerink Partners Downgraded its Outperform to Market Perform on March 11, 2024, whereas the target price for the stock was revised from $27 to $4.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 05 ’24 when Firestone Karen bought 50,000 shares for $2.13 per share. The transaction valued at 106,590 led to the insider holds 55,000 shares of the business.
MILNE GEORGE M JR bought 100,000 shares of AMLX for $219,800 on Sep 03 ’24. The Director now owns 858,571 shares after completing the transaction at $2.20 per share. On May 14 ’24, another insider, Quimi Daphne, who serves as the Director of the company, bought 2,750 shares for $1.89 each. As a result, the insider paid 5,184 and bolstered with 2,750 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 181099440 and an Enterprise Value of -125571632. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.61 while its Price-to-Book (P/B) ratio in mrq is 0.69. Its current Enterprise Value per Revenue stands at -0.42 whereas that against EBITDA is 0.711.
Stock Price History:
Over the past 52 weeks, AMLX has reached a high of $20.99, while it has fallen to a 52-week low of $1.58. The 50-Day Moving Average of the stock is 29.85%, while the 200-Day Moving Average is calculated to be -62.02%.
Shares Statistics:
According to the various share statistics, AMLX traded on average about 1.60M shares per day over the past 3-months and 795360 shares per day over the past 10 days. A total of 67.71M shares are outstanding, with a floating share count of 41.22M. Insiders hold about 39.45% of the company’s shares, while institutions hold 61.50% stake in the company. Shares short for AMLX as of 1723680000 were 1971065 with a Short Ratio of 1.23, compared to 1721001600 on 3778482. Therefore, it implies a Short% of Shares Outstanding of 1971065 and a Short% of Float of 3.19.
Earnings Estimates
The dynamic stock of Amylyx Pharmaceuticals Inc (AMLX) is currently attracting attention from 4.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.42 and low estimates of -$0.66.
Analysts are recommending an EPS of between -$3.79 and -$4.7 for the fiscal current year, implying an average EPS of -$4.13. EPS for the following year is -$1.91, with 5.0 analysts recommending between -$1.4 and -$2.9.
Revenue Estimates
A total of 6 analysts have provided revenue estimates for AMLX’s current fiscal year. The highest revenue estimate was $87.62M, while the lowest revenue estimate was $87.6M, resulting in an average revenue estimate of $87.61M. In the same quarter a year ago, actual revenue was $380.79M
